In:
International Journal of Endocrinology, Hindawi Limited, Vol. 2015 ( 2015), p. 1-10
Abstract:
Background . Multiple weight loss failures among obese patients suggest the design of new therapeutic strategies. We investigated the role of 2-week course of enteral treatment with a very low-calorie protein-based formula in the management of severe obesity. Methods . We evaluated the feasibility, safety, and efficacy of 2-week continuous administration of a protein-based formula (1.2 g/kg of ideal body weight/day) by nasogastric tube in severely obese adults (body mass index (BMI) ≥ 40 kg/m 2 ). Results . In total, 364 patients (59% women; BMI = 46.6 ± 7.2 kg/m 2 ) were recruited. The intervention was discontinued within 48 hours in 26 patients, due to nasogastric tube intolerance. No serious adverse events occurred. During the first and the second week, 65% and 80% patients, respectively, reported no side effects. All biochemical safety parameters were affected by the intervention, particularly uric acid (+45%) and aminotransferases (+48%). In the other cases the change was negligible. We observed significant weight loss ( 5.7 ± 2.3 %) and improvement in blood pressure and glucose and lipid metabolism parameters ( P 〈 0.001 ). Conclusions . A 2-week course of enteral treatment with a very low-calorie protein-based formula appeared a feasible, likely safe, and efficacious therapeutic option to be considered for inclusion into a composite weight loss program for the management of severe obesity. This trial is registered with ClinicalTrials.gov Identifier: NCT01965990 .
Type of Medium:
Online Resource
ISSN:
1687-8337
,
1687-8345
Language:
English
Publisher:
Hindawi Limited
Publication Date:
2015
detail.hit.zdb_id:
2502951-4
